- Do you own shares of CoLucid Pharmaceuticals, Inc. (NASDAQ GM: CLCD)?
- Did you purchase any of your shares prior to January 18, 2017?
- Do you think the proposed buyout price is too low?
Please contact Rigrodsky & Long, P.A. (“R & L”) to schedule a free consultation. You may call us or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.
R & L is investigating potential claims against the board of directors of CoLucid Pharmaceuticals, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Eli Lilly and Company for $46.50, or approximately $960 million.